Main Article Content

Dolutegravir for second-line treatment: Programmatic implications of new evidence


Ying Zhao
Gary Maartens
Graeme Meintjes

Abstract

No Abstract


Journal Identifiers


eISSN: 2078-6751
print ISSN: 1608-9693